Akiko Itai Selected Research

I-kappa B Kinase

4/2019	A novel IkB kinase inhibitor attenuates ligature-induced periodontal disease in mice.
1/2009	Antiallergic and anti-inflammatory effects of a novel I kappaB kinase beta inhibitor, IMD-0354, in a mouse model of allergic inflammation.
1/2009	Effectiveness of IkappaB kinase inhibitors in murine colitis-associated tumorigenesis.
3/2008	Inhibition of IkappaB kinase beta restrains oncogenic proliferation of pancreatic cancer cells.
2/2008	Activation of IkappaB kinase and NF-kappaB is essential for Helicobacter pylori-induced chronic gastritis in Mongolian gerbils.
5/2006	A novel IkappaB kinase-beta inhibitor ameliorates bleomycin-induced pulmonary fibrosis in mice.
1/2006	A new IkappaB kinase beta inhibitor prevents human breast cancer progression through negative regulation of cell cycle transition.
10/2004	A novel IKKbeta inhibitor stimulates adiponectin levels and ameliorates obesity-linked insulin resistance.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Akiko Itai Research Topics

Disease

17	Inflammation (Inflammations) 01/2020 - 05/2006
8	Neoplasms (Cancer) 05/2016 - 01/2006
3	Ovarian Neoplasms (Ovarian Cancer) 10/2017 - 04/2015
3	Asthma (Bronchial Asthma) 01/2015 - 01/2009
3	Myocarditis (Carditis) 12/2013 - 11/2008
3	Fibrosis (Cirrhosis) 12/2012 - 01/2007
3	Myocardial Ischemia (Ischemic Heart Diseases) 03/2011 - 12/2008
3	Thrombosis (Thrombus) 02/2011 - 07/2008
2	Uveitis 01/2020 - 01/2012
2	Hypertrophy 01/2015 - 12/2012
2	Rheumatoid Arthritis 12/2014 - 08/2005
2	Cardiovascular Diseases (Cardiovascular Disease) 01/2012 - 02/2011
2	Arthritis (Polyarthritis) 03/2011 - 08/2005
2	Ventricular Remodeling 01/2011 - 01/2007
2	Reperfusion Injury 01/2011 - 07/2004
2	Carcinogenesis 01/2009 - 01/2006
2	Infarction (Infarctions) 01/2007 - 07/2004
2	Body Weight (Weight, Body) 05/2006 - 10/2004
2	Leukemia 01/2006 - 06/2005
1	Edema (Dropsy) 01/2020
1	Periodontal Diseases (Periodontal Disease) 04/2019
1	Periodontitis 04/2019
1	Bone Resorption 04/2019
1	Adenocarcinoma 10/2017
1	Neoplasm Metastasis (Metastasis) 05/2016
1	Infections 03/2016
1	Chorioamnionitis 03/2016
1	Airway Remodeling 01/2015
1	Squamous Cell Carcinoma of Head and Neck 12/2014
1	Diabetic Retinopathy (Retinopathy, Diabetic) 09/2014
1	Pulmonary Arterial Hypertension 07/2013
1	Cardiomegaly (Heart Hypertrophy) 12/2012
1	Adult T-Cell Leukemia-Lymphoma (Leukemia Lymphoma, T Cell, Acute, HTLV I Associated) 01/2012
1	Hypertension (High Blood Pressure) 02/2011
1	Vascular Remodeling 02/2011
1	Arterial Occlusive Diseases (Arterial Occlusive Disease) 01/2011
1	Hypersensitivity (Allergy) 01/2009
1	Colitis-Associated Neoplasms 01/2009
1	Colitis 01/2009
1	Respiratory Hypersensitivity 01/2009
1	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2009
1	Heart Failure 12/2008
1	Neointima 07/2008
1	Pancreatic Neoplasms (Pancreatic Cancer) 03/2008
1	Gastritis 02/2008
1	Atopic Dermatitis (Atopic Eczema) 04/2007
1	Pheochromocytoma 04/2007
1	Dermatitis 04/2007

Drug/Important Bio-Agent (IBA)

15	N- (3,5- bis(trifluoromethyl)phenyl)- 5- chloro- 2- hydroxybenzamideIBA 01/2020 - 07/2004
14	NF-kappa B (NF-kB)IBA 04/2019 - 07/2004
9	Phosphotransferases (Kinase)IBA 04/2019 - 03/2008
8	I-kappa B KinaseIBA 04/2019 - 10/2004
7	Plasminogen Activator Inhibitor 1IBA 10/2017 - 07/2008
5	Plasminogen Activators (Plasminogen Activator)IBA 10/2017 - 11/2008
5	CytokinesIBA 03/2016 - 07/2004
4	N- (2,5- bis(trifluoromethyl)phenyl)- 5- bromo- 2- hydroxybenzamideIBA 05/2016 - 08/2005
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 05/2016 - 04/2015
2	Pharmaceutical PreparationsIBA 04/2015 - 01/2012
2	IMD-1041IBA 12/2012 - 01/2012
2	Proteins (Proteins, Gene)FDA Link 02/2011 - 02/2011
2	Matrix Metalloproteinases (MMPs)IBA 01/2011 - 12/2008
1	Therapeutic UsesIBA 01/2020
1	Indicators and Reagents (Reagents)IBA 04/2019
1	Urokinase-Type Plasminogen Activator (Urokinase)FDA Link 10/2017
1	VitronectinIBA 10/2017
1	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 10/2017
1	IntegrinsIBA 10/2017
1	Focal Adhesion Protein-Tyrosine KinasesIBA 10/2017
1	Interleukin-6 (Interleukin 6)IBA 03/2016
1	CollagenIBA 01/2015
1	AllergensIBA 01/2015
1	2- ((3- (4- tert- butylphenoxy)- 4'- (trifluoromethoxy)(1,1'- biphenyl)- 4- yl)oxy)acetic acidIBA 01/2015
1	Streptozocin (Streptozotocin)FDA Link 09/2014
1	Cardiac MyosinsIBA 12/2013
1	EndotoxinsIBA 01/2012
1	ProdrugsIBA 01/2012
1	OsteopontinIBA 02/2011
1	AldosteroneIBA 02/2011
1	Fibrinogen (Factor I)FDA Link 02/2011
1	Collagen Type I (Type I Collagen)IBA 02/2011
1	Plasminogen InactivatorsIBA 01/2011
1	Fibrinolysin FDA Link 01/2011
1	benzamideIBA 01/2009
1	AzoxymethaneIBA 01/2009
1	Peptides (Polypeptides)IBA 01/2009
1	Transcription Factors (Transcription Factor)IBA 01/2009
1	Dextran SulfateIBA 01/2009
1	ChemokinesIBA 01/2009
1	Anti-Allergic Agents (Antiallergic Agents)IBA 01/2009
1	3- (3,4- dichlorobenzyl)- 5- (3,4,5- trihydroxybenzylidene)thiazolidine- 2,4- dioneIBA 07/2008
1	AgarIBA 03/2008
1	Clodronic Acid (Clodronate)IBA 02/2008
1	Immunoglobulin E (IgE)IBA 04/2007
1	Nerve Growth Factor (NGF)IBA 04/2007
1	Ointments (Pastes)IBA 04/2007
1	Tacrolimus (Prograf)FDA LinkGeneric 04/2007

Therapy/Procedure

2	Ligation 04/2019 - 01/2007
2	Therapeutics 04/2015 - 03/2008
1	Heart Transplantation (Grafting, Heart) 01/2011
1	Sutures (Suture) 01/2011